{"id":124,"date":"2018-11-30T14:38:18","date_gmt":"2018-11-30T14:38:18","guid":{"rendered":"https:\/\/admin.innaxon.co.uk\/?page_id=124"},"modified":"2018-11-30T14:38:24","modified_gmt":"2018-11-30T14:38:24","slug":"iaxo-101-cd14-tlr4-antagonist-synthetic","status":"publish","type":"page","link":"https:\/\/wp.innaxon.co.uk\/?page_id=124","title":{"rendered":"IAXO-101 (CD14\/TLR4 Antagonist) (synthetic)"},"content":{"rendered":"<p><strong>Product Size<\/strong><\/p>\n<p>1mg:\u00a0\u00a3<span id=\"_EKM_PRODUCTPRICE\">140.16<\/span><\/p>\n<p>5mg:\u00a0\u00a3<span id=\"_EKM_PRODUCTPRICE\">350.96<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Product Number<\/strong><\/p>\n<p>1mg: IAX-600-001-M001<\/p>\n<p>5mg: IAX-600-001-M005<\/p>\n<p>&nbsp;<\/p>\n<p>Methyl 6-deoxy-6-N-dimethyl-N-cyclopentylammonium-2, 3-di-O-tetradecyl-\u03b1-D-glucopyranoside iodide<\/p>\n<p><strong>Synonyms:<\/strong> FP1. Small molecule CD14\/TLR4 ligand\/modulator. Glycolipid. Lipid A analogue. Inhibitor of sterile inflammation.<\/p>\n<p>Persistent inflammation has been implicated in the pathogenesis not only of diverse chronic diseases such as neuropathic pain, atherosclerosis, chronic hepatitis, and abdominal aortic aneurysm, but also acute organ failure, cardiac infarct and stroke.<\/p>\n<p>The Toll-like receptor (TLR) family members are key contributors to these pro- inflammatory conditions. These pattern recognition receptors respond to molecular patterns in components of bacteria and viruses. In addition to their role in detecting pathogen associated molecular patterns (PAMPs), TLRs can also sense endogenous danger (or tissue damage) associated molecular patterns (DAMPs) and have been implicated in perpetuating inflammatory cascades in the absence of invading microbes or other pathogens.<\/p>\n<p>TLR4\u2019s well-known key role in orchestrating innate and adaptive immune response to Gram-negative bacteria now extends into the area of mediating auto-inflammation and tissue repair and re-modelling.<\/p>\n<p>IAXO compounds hold considerable promise in pharmacological settings, where inhibition of sterile (auto-) inflammation is desired, without compromising TLR4\u2019s key role in the defense of pathogens. CD14-dependent and independent TLR4 activation in the central nervous system by endogenous factors has been recently related to a wide array of inflammatory neurological diseases such as amyotrophic lateral sclerosis and Alzheimer\u2019s disease.<\/p>\n<hr \/>\n<p><b>Product Specific References<\/b><\/p>\n<p>[1] <i>Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization<\/i>. Piazza M, et al. J. Med. Chem. (2009); 52:1209<br \/>\n[2] <i>Glia TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice. <\/i>Bettoni I, et al. Glia (2008); 56:1312<br \/>\n[3] I<i>nhibition of lipid a stimulated activation of human dendritic cells and macrophages by amino and hydroxylamino monosaccharides. <\/i><br \/>\nPeri F, et al. Angew .Chem. (2007); 46:3308<br \/>\n[4] <i>Evidence of a specific interaction between new synthetic antisepsis agents and CD14. <\/i>Piazza M, et al. Biochemistry (2009); 48:12337<br \/>\n[5] <i>Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. <\/i>Peri F, Piazza M. Biotechnol. Adv. (2012); 30:251 REVIEW<br \/>\n[6] <i>Synthetic molecules and functionalized nanoparticles targeting the LPS-TLR4 signaling: A new generation of immunotherapeutics. <\/i>Peri F, Calabrese V, Piazza M, Cighetti R.Pure Appl. Chem. (2012); 84:97 REVIEW<br \/>\n[7]\u00a0<em>Inhibition of the cluster of differentiation 14 innate immunity pathway with IAXO-101 improves chronic microelectrode performance<\/em>.<i>\u00a0<\/i>Hermann JK., et al. J Neural Eng (2017) [Epub ahead of print]\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29219114\" target=\"_blank\" rel=\"noopener\">PubMed Abstract<\/a><\/p>\n<hr \/>\n<p><b>Inactive Control Compound<\/b><br \/>\n<a href=\"http:\/\/innaxon.co.uk\/iaxo-202-control-for-iaxo-101--iaxo-103-synthetic-252-p.asp\">IAXO-202 (Control for IAXO-101 \/ IAXO-103) (synthetic)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Product Size 1mg:\u00a0\u00a3140.16 5mg:\u00a0\u00a3350.96 &nbsp; Product Number 1mg: IAX-600-001-M001 5mg: IAX-600-001-M005 &nbsp; Methyl 6-deoxy-6-N-dimethyl-N-cyclopentylammonium-2, 3-di-O-tetradecyl-\u03b1-D-glucopyranoside iodide Synonyms: FP1. Small molecule CD14\/TLR4 ligand\/modulator. Glycolipid. Lipid A analogue. Inhibitor of sterile inflammation. Persistent inflammation has been implicated in the pathogenesis not only of diverse chronic diseases such as neuropathic pain, atherosclerosis, chronic hepatitis, and abdominal aortic aneurysm, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":53,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-124","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IAXO-101 (CD14\/TLR4 Antagonist) (synthetic) -<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wp.innaxon.co.uk\/?page_id=124\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IAXO-101 (CD14\/TLR4 Antagonist) (synthetic) -\" \/>\n<meta property=\"og:description\" content=\"Product Size 1mg:\u00a0\u00a3140.16 5mg:\u00a0\u00a3350.96 &nbsp; Product Number 1mg: IAX-600-001-M001 5mg: IAX-600-001-M005 &nbsp; Methyl 6-deoxy-6-N-dimethyl-N-cyclopentylammonium-2, 3-di-O-tetradecyl-\u03b1-D-glucopyranoside iodide Synonyms: FP1. Small molecule CD14\/TLR4 ligand\/modulator. Glycolipid. Lipid A analogue. Inhibitor of sterile inflammation. Persistent inflammation has been implicated in the pathogenesis not only of diverse chronic diseases such as neuropathic pain, atherosclerosis, chronic hepatitis, and abdominal aortic aneurysm, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wp.innaxon.co.uk\/?page_id=124\" \/>\n<meta property=\"article:modified_time\" content=\"2018-11-30T14:38:24+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=124\",\"url\":\"https:\/\/wp.innaxon.co.uk\/?page_id=124\",\"name\":\"IAXO-101 (CD14\/TLR4 Antagonist) (synthetic) -\",\"isPartOf\":{\"@id\":\"https:\/\/wp.innaxon.co.uk\/#website\"},\"datePublished\":\"2018-11-30T14:38:18+00:00\",\"dateModified\":\"2018-11-30T14:38:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=124#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/wp.innaxon.co.uk\/?page_id=124\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=124#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/wp.innaxon.co.uk\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TLR4\/CD14 Inhibitors IAXO (synthetic)\",\"item\":\"https:\/\/wp.innaxon.co.uk\/?page_id=53\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IAXO-101 (CD14\/TLR4 Antagonist) (synthetic)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/wp.innaxon.co.uk\/#website\",\"url\":\"https:\/\/wp.innaxon.co.uk\/\",\"name\":\"\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/wp.innaxon.co.uk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IAXO-101 (CD14\/TLR4 Antagonist) (synthetic) -","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wp.innaxon.co.uk\/?page_id=124","og_locale":"en_GB","og_type":"article","og_title":"IAXO-101 (CD14\/TLR4 Antagonist) (synthetic) -","og_description":"Product Size 1mg:\u00a0\u00a3140.16 5mg:\u00a0\u00a3350.96 &nbsp; Product Number 1mg: IAX-600-001-M001 5mg: IAX-600-001-M005 &nbsp; Methyl 6-deoxy-6-N-dimethyl-N-cyclopentylammonium-2, 3-di-O-tetradecyl-\u03b1-D-glucopyranoside iodide Synonyms: FP1. Small molecule CD14\/TLR4 ligand\/modulator. Glycolipid. Lipid A analogue. Inhibitor of sterile inflammation. Persistent inflammation has been implicated in the pathogenesis not only of diverse chronic diseases such as neuropathic pain, atherosclerosis, chronic hepatitis, and abdominal aortic aneurysm, [&hellip;]","og_url":"https:\/\/wp.innaxon.co.uk\/?page_id=124","article_modified_time":"2018-11-30T14:38:24+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/wp.innaxon.co.uk\/?page_id=124","url":"https:\/\/wp.innaxon.co.uk\/?page_id=124","name":"IAXO-101 (CD14\/TLR4 Antagonist) (synthetic) -","isPartOf":{"@id":"https:\/\/wp.innaxon.co.uk\/#website"},"datePublished":"2018-11-30T14:38:18+00:00","dateModified":"2018-11-30T14:38:24+00:00","breadcrumb":{"@id":"https:\/\/wp.innaxon.co.uk\/?page_id=124#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wp.innaxon.co.uk\/?page_id=124"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/wp.innaxon.co.uk\/?page_id=124#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/wp.innaxon.co.uk\/"},{"@type":"ListItem","position":2,"name":"TLR4\/CD14 Inhibitors IAXO (synthetic)","item":"https:\/\/wp.innaxon.co.uk\/?page_id=53"},{"@type":"ListItem","position":3,"name":"IAXO-101 (CD14\/TLR4 Antagonist) (synthetic)"}]},{"@type":"WebSite","@id":"https:\/\/wp.innaxon.co.uk\/#website","url":"https:\/\/wp.innaxon.co.uk\/","name":"","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/wp.innaxon.co.uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=124"}],"version-history":[{"count":1,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/124\/revisions"}],"predecessor-version":[{"id":125,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/124\/revisions\/125"}],"up":[{"embeddable":true,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/53"}],"wp:attachment":[{"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}